Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for UROGEN PHARMA LTD Common Stock (URGN).
- Disclosed ownership: 5%.
- Date of event: 30 Jun 2025.
BlackRock, Inc. - 30 Jun 2025 SCHEDULE 13G/A Report for UROGEN PHARMA LTD Common Stock (URGN)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Security
- UROGEN PHARMA LTD Common Stock
- Symbol
- URGN
- Shares outstanding
- 45,684,120 shares
- Disclosed Ownership
- 2,284,206 shares
- Ownership
- 5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 16 Jul 2025, 19:02:15 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 5% ownership in UROGEN PHARMA LTD Common Stock (URGN) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 16 Jul 2025, 19:02.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5% | 2,284,206 | 2,238,946 | 0 | Spencer Fleming | Managing Director |